Centogene N V (CNTG) Return on Equity ROE from the fourth quarter 2023 to fourth quarter 2022 and annually, average high and low, overall ranking from Dec 31 2023 to Dec 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Centogene N v   (NASDAQ: CNTG)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Centogene N V 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Centogene N V in the fourth quarter 2023?
Due to the lack of equity, it was not possible to calculate Centogene N V 's return on equity (ROE) in its fourth quarter 2023

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2023)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2022)
IV. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -40 -36 -36 -47 -54
Return On Equity (TTM) - - - - -364.76 %
CNTG's Total Ranking # # # # #
Equity (TTM) in Millions -28 -28 -28 -28 8
Seq. Equity Change - - - - 0 %
Seq. Net Income Change - - - - -

Back to CNTG Management Effectiveness >> CNTG's 5 Years Annual ROE >> Compare CNTG ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 



  News about Centogene N v Return on Equity ROE

Fueling Medical Research: CENTOGENE Receives French Accreditation for Research Tax Credit



CENTOGENE, a leading global provider of diagnostic and research solutions in rare diseases, has announced its successful accreditation for the French Research Tax Credit. This achievement allows CENTOGENE s partners to claim up to 30% tax relief, thereby providing significant financial advantages and promoting further collaboration in the field of medical research.
The company s year-to-date performance stands at an impressive 6.84%, reflecting CENTOGENE s commitment to leveraging innovative technologies and scientific expertise to make a meaningful impact on patients lives. The recent accreditation for the French Research Tax Credit adds another feather to their cap, exemplifying their continuous pursuit of excellence.

Centogene N.V. Reports Steady Revenue Growth for Full Year 2023 in Rare and Neurodegenerative Diseases



Centogene N.V., a prominent life science company specializing in data-driven solutions for rare and neurodegenerative diseases, has recently released its preliminary unaudited revenue figures for the full year of 2023. The company s revenue for this period is estimated to be between approximately 48.5 million and 49.0 million, showcasing a growth rate in the mid-single digits compared to 2022.
Based in Cambridge, Massachusetts, as well as Rostock and Berlin in Germany, Centogene N.V. has established itself as a crucial partner in the field of rare and neurodegenerative diseases. By utilizing innovative technologies and cutting-edge analytics, the company provides essential answers to patients, physicians, and researchers alike.



CNTG Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2017)
2019
Total Equity in Millions -28 8 27 65 30
Y / Y Equity Change - -69.69 % -57.99 % 114.53 % -
Net Income in Millions -40 -36 -52 -25 -6
Y / Y Net Income Change - - - - -
Return On Equity - -429.65 % -191.62 % -38.48 % -20.37 %

Back to CNTG Management Effectiveness >> CNTG's 5 Years Annual ROE >> Compare CNTG ROE to its Competitors




More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CNTG's' Return on Equity at Yahoo Finance
CNTG's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CNTG's Competitors
Subscribers only: Roe for Centogene N V 's Suppliers
Subscribers only: Return On Equity for CNTG's Customers




Companies with similar Return On Equity at Dec 31 2023, within Healthcare Sector ROE
Ir med Inc   370.14 %
Mimedx Group Inc   237.80 %
Halozyme Therapeutics Inc   204.84 %
Glucotrack Inc   171.97 %
Roivant Sciences Ltd   160.44 %
Ladrx Corporation  152.84 %
Biomx Inc  140.47 %
Icecure Medical Ltd  120.46 %
Scynexis Inc   117.56 %
Viskase Holdings inc   114.23 %
Amgen Inc   103.27 %
Entera Bio Ltd   101.78 %
Profound Medical Corp   91.63 %
Waters Corporation  87.01 %
Dariohealth Corp   85.94 %
Cv Sciences Inc   80.98 %
Davita Inc   78.94 %
Novo Nordisk A  76.82 %
Galmed Pharmaceuticals Ltd   74.21 %
Idexx Laboratories Inc  71.66 %
Medpace Holdings Inc   63.98 %
Voyager Therapeutics Inc   63.89 %
Puma Biotechnology Inc   58.19 %
Enzo Biochem Inc  53.73 %
Lantheus Holdings Inc   52.00 %
Johnson and Johnson  48.95 %
Zoetis Inc   48.81 %
Nrc Health  47.79 %
Eli Lilly And Company  46.98 %
Elite Pharmaceuticals Inc   46.73 %

Date modified: 2026-09-08T15:11:16+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.